February 13, 2024 07:26 AM ESTUpdated 09:20 AM
R&D

G1 Ther­a­peu­tic­s' stock sinks near­ly 40% on PhI­II read­out de­lay

Katherine Lewin

News Reporter

G1 Ther­a­peu­tics an­nounced that it will be con­tin­u­ing its Phase III breast can­cer tri­al for its drug Cosela fol­low­ing an in­ter­im analy­sis, push­ing back a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times